Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

NCT03597516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

557

Enrollment

INDUSTRY

Sponsor class

Conditions

Lactose Intolerance

Interventions

DRUG: RP-G28
DRUG: Placebos

Sponsor

Ritter Pharmaceuticals, Inc.